A physiologically-based toxicokinetic and toxicodynamic (PBTK/TD) model was developed, from the open literature, to predict the toxicokinetic disposition and toxicodynamic response (acetylcholinesterase inhibition) of a ternary organophosphorus (OP) insecticide mixture: chlorpyrifos (CP), methyl parathion (MP) and parathion (P). In vivo studies were conducted in adult male Sprague-Dawley rats, orally administered one of two CP/MP/P mixtures (2.5, 0.5, 0.5 mg/kg or 5, 1, 1 mg/kg) with selected tissues (blood, brain, diaphragm, liver, lung and skeletal muscle) collected at 30min, 4, 12 and 24hr postdosing. Low dosages were studied so the mixture did not result in significant disruption of cardiovascular function nor invalidate the model’s underlying general physiological assumptions. The data were used to validate the model. CP and its metabolites (CP-oxon, 3,5,6-trichloro-2-pyridinol (TCP)), as well as MP, P and 4-nitrophenol, were quantified in the tissues of interest. Peak concentrations of CP were attained by 4hr in all tissues with the exception of the liver, whose peak occurred at 30min; MP, 30min in all tissues; P, 12hr in all tissues with the exception of the liver, 30min. This was supported by the model simulations. MP, P, and their respective oxons were below limits of quantitation for the lower dosage. No toxicokinetic interactions were observed in the present study. Cholinesterase inhibition in the tissues ranged from 11- 37% for the lower dosage, and 29-93% for the higher dosage group; with few exceptions, inhibition was generally additive and was also supported by the model simulations. This study demonstrates the utility of using previously developed individual PBTK/TD models and in vitro/in vivo data from the open literature to construct reliable mixture PBTK/TD models.

No description available.

No description available.

No description available.

No description available.

No description available.

No description available.

The group of chemicals designated organophosphorus compounds have had a significant impact on modern life, including use as pesticides, industrial plasticizers and chemical warfare agents. Exposure to certain organophosphates produces a delayed degeneration of the longest and largest nerve fibers, including those of the ascending and descending tracts of the spinal cord, a condition termed organophosphorus ester-induced delayed neuropathy (OPIDN). Recorded incidents of such an effect in humans have led to research regarding this neurological disease. Among the OPIDN-inducing agents is mipafox, an organophosphate insecticide, the compound we chose to employ in our studies. Although the hen is the primary experimental model in the safety assessment of organophosphates, current research has suggested that the rat may have some validity as an experimental model. We examined the sequential neuropathic effects of a single dose of mipafox (30mg/kg) in rats and hens on a comparative basis to determine the better experimental model. / Master of Science

The contribution of the cardiovascular system. to organophosphate-induced delayed neuropathy (OPIDN) was examined using in situ and in vitro models for demonstration of response to vasoactive agents (e.g., the cholinergic agonist, acetylcholine; the α1 agonist, phenylephrine; and the β2 agonist, salbutamol). These responses were compared before and 1, 3, 7, and 21 days after hens were administered cyclic phenyl saligenin phosphate (PSP, 2.5 mg/kg i.m.), an OP that induces OPIDN but does not significantly inhibit acetylcholinesterase activity, and paraoxon (PXN, 0.1 mg/kg i.m.), an OP that inhibits acetylcholinesterase activity but does not induce OPIDN. The capability of verapamil, a calcium channel blocker, to attenuate these responses was examined, as this agent ameliorates OPIDN. For the in situ study, the ischiadic artery was cannulated and alterations in pressure measured at a constant flow used to indicate changes in vascular resistance. Changes in vascular resistance in response to acetylcholine, phenylephrine, and salbutamol that were different from those in control and PXN-treated hens were noted 1 and 3 days after administration of PSP. These changes were attenuated in hens given PSP and verapamil. Vascular segments from the ischiadic artery were used to provide an in vitro model to determine if OPs caused direct vascular damage that was responsible for effects seen in the in situ model. In the in vitro model, however, responses of PSP and PXN were similar and not modified in vascular segments from hens given verapamil as well as the OPs. This indicated that the contribution of the cardiovascular system to OPIDN was due to more than a direct effect on relatively large caliber vessels. The contribution of the cardiovascular system to OPIDN also did not appear to relate to morphological changes induced by administration of OPs, as no changes in vascular morphology were noted. An OP-induced effect that could contribute to vascular effects noted are levels of plasma catecholamines. These levels were altered in hens given PSP or PXN, with increases seen after administration of PSP and decreases seen after administration of PXN. These alterations in plasma catecholamine levels were attenuated in hens given both verapamil and OP. / Ph. D.

Organophosphorus compounds are widely used in agriculture as pesticides and in industry as petroleum additives and modifiers of plastics. Some of these compounds are capable of inducing an irreversible neuropathy developing weeks to months after exposure, yet there is no effective treatment. This may be due in part to the lack of knowledge of how this neuropathy develops. In this dissertation, it is proposed that as a consequence of a triggering event, peripheral nerves may be predisposed to an increase in calcium (Ca⁺⁺) mobilization and the neuronal accumulation of this cation. This increase in Ca could thereby initiate a cascade of events, in both nerve and muscle, that may account for some of the detrimental changes occurring during organophosphorus-induced delayed neuropathy (OPIDN). The involvement of Ca⁺⁺ in the pathogenesis of OPIDN was tested using functional, morphological, and biochemical techniques in the domestic hen, the recognized animal model of OPIDN. The isolated biventer cervicis nerve-muscle preparation was developed for quick assessment of the time course of OPIDN deficits and validated by comparison to in vivo preparations. This preparation proved more sensitive by functional and morphological evaluation indicating early damage at 4 days following exposure and before appearance of clinical signs. Regeneration was detected after 21 days. OPIDN was modified by using Ca⁺⁺ channel blockers, nifedipine, and verapamil, in the presence of phenyl saligenin phosphate, an active neurotoxicant. Attenuation of OPIDN by these compounds was revealed by clinical assessment, by changes in nerve excitability denoted by strength-duration relationships in response to electrical stimulation, by denervation hypersensitivity to neurotransmitter, and by morphology. These modifiers attenuated all degenerative responses. Furthermore, it was revealed that the activity of Ca⁺⁺-activated neutral protease (CANP), an enzyme responsible for neurofilament degradation, was increased in OPIDN. Such increases were ameliorated by modifiers of Ca movement. This study strongly suggests that Ca⁺⁺, possibly through activation of CANP, may contribute to functional and morphological deficits of OPIDN. / Ph. D.